Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (14)

2024

  1. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR–MASH score

    Liver International, Vol. 44, Núm. 1, pp. 202-213

2023

  1. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

2022

  1. Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease

    Radiology, Vol. 302, Núm. 2, pp. 345-354

  2. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Digital pathology enables automated and quantitative assessment of inflammatory activity in patients with chronic liver disease

    Biomolecules, Vol. 11, Núm. 12

  2. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 200-219

2019

  1. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study

    PLoS ONE, Vol. 14, Núm. 9

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain

    Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486

2010

  1. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response

    American Journal of Gastroenterology, Vol. 105, Núm. 10, pp. 2164-2172

2008

  1. Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis

    Hepatology, Vol. 48, Núm. 6, pp. 1924-1931